Lantheus Holdings, Inc.

How big is Lantheus Holdings, Inc.?

As of Jun 18, Lantheus Holdings, Inc. has a market capitalization of $5.39 billion, with net sales of $1.54 billion and a net profit of $254.31 million over the last four quarters.

Market Cap: As of Jun 18, Lantheus Holdings, Inc. has a market capitalization of 5,390.96 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Lantheus Holdings, Inc. reported net sales of 1,536.69 million and a net profit of 254.31 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 1,088.01 million, while total assets were reported at 2,015.11 million.

What does Lantheus Holdings, Inc. do?

Lantheus Holdings, Inc. develops and commercializes diagnostic medical imaging agents in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $373 million and a net profit of $73 million, with a market cap of approximately $5.39 billion.

Overview:<BR>Lantheus Holdings, Inc. is engaged in the development, manufacture, and commercialization of diagnostic medical imaging agents and products within the Pharmaceuticals & Biotechnology industry, categorized as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 373 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 73 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 5,390.96 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 15.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.32 <BR>Return on Equity: 31.84% <BR>Price to Book: 4.63<BR><BR>Contact Details:<BR>Address: 331 Treble Cove Rd, NORTH BILLERICA MA: 01862-2849 <BR>Tel: 1 978 6718001 <BR>Fax: 1 302 6365454 <BR>Website: http://www.lantheus.com/

Should I buy, sell or hold Lantheus Holdings, Inc.?

Who are in the management team of Lantheus Holdings, Inc.?

As of March 2022, the management team of Lantheus Holdings, Inc. includes Non-Executive Independent Chairman Brian Markison, President and CEO Mary Heino, and Independent Directors Gerard Ber, James Clemmer, Samuel Leno, and Heinz Maeusli, who oversee the company's strategic direction and operations.

As of March 2022, the management team of Lantheus Holdings, Inc. includes the following individuals:<BR><BR>- Mr. Brian Markison, who serves as the Non-Executive Independent Chairman of the board.<BR>- Ms. Mary Heino, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Gerard Ber, who is an Independent Director.<BR>- Mr. James Clemmer, who is also an Independent Director.<BR>- Mr. Samuel Leno, who serves as an Independent Director.<BR>- Mr. Heinz Maeusli, who is another Independent Director.<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Is Lantheus Holdings, Inc. technically bullish or bearish?

As of August 6, 2025, Lantheus Holdings, Inc. is in a bearish trend, indicated by negative MACD signals and underperformance with a year-to-date return of -42.37% compared to the S&P 500's 12.22%.

As of 6 August 2025, the technical trend for Lantheus Holdings, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from the weekly and monthly MACD, both of which are bearish. The daily moving averages also confirm a bearish trend. The Bollinger Bands are bearish on both weekly and monthly time frames, and the KST is bearish weekly and mildly bearish monthly. The RSI shows no signal weekly but is bullish monthly, indicating some divergence. <BR><BR>In terms of performance, Lantheus has underperformed significantly compared to the S&P 500, with a year-to-date return of -42.37% versus the S&P 500's 12.22%, and a one-year return of -52.32% compared to 17.14% for the index.

Is Lantheus Holdings, Inc. overvalued or undervalued?

As of October 17, 2025, Lantheus Holdings, Inc. is considered undervalued with a P/E ratio of 15 and an EV to EBITDA of 10.33, despite a recent year-to-date return of -37.85%, suggesting potential for recovery compared to its peers like QIAGEN NV, which has a P/E of 24.20.

As of 17 October 2025, Lantheus Holdings, Inc. has moved from fair to attractive in its valuation grade. The company appears to be undervalued, with a P/E ratio of 15, an EV to EBITDA of 10.33, and an impressive ROCE of 56.47%. In comparison, QIAGEN NV has a P/E of 24.20, indicating that Lantheus is trading at a significant discount relative to some of its peers.<BR><BR>Additionally, while Lantheus has shown strong performance in the past five years with a return of 316.48%, it has struggled recently, with a year-to-date return of -37.85%, compared to the S&P 500's 13.30%. This stark contrast highlights the potential for recovery and growth in Lantheus's valuation moving forward.